Arvee Laboratories (India) Limited (ARVEE) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Arvee Laboratories (India) Limited ₹33.72, price ₹213, upside -84.2%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Stretched ValuationStrong overvaluation with only moderate quality.
!Fair value ₹33.72 · Strongly overvalued (−84.2%)
!Quality 51/100
!Weak Growth(revenue 5y −7.7 %/yr)
!Thin margins · 8.0% net margin (TTM)
!Low debt · negative free cash flow
!Mixed vs. peers(6/12)
!Narrow moat39/100
!Evidence only low, so the estimate is less certain
Watch Arvee Laboratories (India) Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹64.45 – ₹306.70 · fair‑value band ₹23.60 – ₹43.83 · the ₹213.19 price screens above the ₹33.72 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Arvee Laboratories (India) in your weekly email
Every Wednesday you see whether Arvee Laboratories (India) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India.
Show more
Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company offers polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, and dimethyl 5-aminoisophthalate, as well as 3,5-dinitrobenzoic acid and 3,5-diamino benzoic acid. It also provides drug intermediates comprising 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4"amino pyridine, and 2"chloro"5"nitrobenzoic acid. In addition, the company exports its products. Arvee Laboratories (India) Ltd. was incorporated in 2012 and is based in Ahmedabad, India.
Stock analysis
Arvee Laboratories (India) Limited (ARVEE) currently trades at ₹213.19, while our model-based Fair Value estimate is ₹33.72, implying the stock looks roughly 532.1% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹33.72 per share, and 0 of the 15 models we run sit above the ₹213.19 price.
Bear case: the Earnings-Based group reads lowest at ₹11.97, and 15 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹23.60 (bear) to ₹43.83 (bull), the price of ₹213.19 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Arvee Laboratories (India) Limited reported revenue of ₹315M in FY2026 versus ₹403M in FY2022, a compound −6.0%/yr. Reported net income was ₹25.3M in FY2026, compounding −0.5%/yr from FY2022.
Key figures
Market cap ₹2.4B (≈ $24.5M) · P/E ratio 113.4 · P/S ratio 9.09 · EPS (TTM) ₹1.88 · Net margin 8.0% · Return on equity 7.8% · Return on assets (EBIT) 12.0% · Operating margin 7.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 59% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −54% fair-value upside, at −84%, ARVEE screens richer than that median.
Fair Value models
Bear ₹23.60Fair Value ₹33.72Bull ₹43.83
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.9271 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−18.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.7%
Start year 2021 (pandemic). Over 10 years: +1.6% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.6%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−0.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.4% vs 11.2%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 6%
Compare Arvee Laboratories (India) Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 706 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−84.2% · Bottom 25%
Profitability
Return on equity (TTM)7.8% · Above median
Return on assets3.1% · Above median
Net margin (TTM)8.0% · Above median
Operating margin (TTM)7.3% · Above median
Growth and dividend
Revenue growth67.5% · Top 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/E (TTM)113.4× · Priciest 25%
P/B6.96× · Priciest 25%
P/S (TTM)7.46× · Priciest 25%
EV/EBITDA72.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 26
PAST (return on equity)31· sector 23
HEALTH (low debt)98· sector 95
DIVIDEND (yield)0· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Arvee Laboratories (India) Limited (ARVEE) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹33.72 versus a price of ₹213.19, about −84% upside (overvalued).
What is the fair value of ARVEE?
Our model-based fair value for Arvee Laboratories (India) Limited is ₹33.72 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹213.19.
What is the quality score of ARVEE?
Arvee Laboratories (India) Limited has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Arvee Laboratories (India) Limited (ARVEE)?
Our model-based price target is the fair value of ₹33.72 (as of Sep 27, 2026) from 15 valuation models. Cautious scenario ₹23.60, optimistic scenario ₹43.83. It is a calculation from audited fundamentals, not an analyst target.
What is the Arvee Laboratories (India) Limited stock forecast for 2026?
Our models put fair value at ₹33.72, about −84% upside versus a price of ₹213.19 (overvalued). Cautious scenario ₹23.60, optimistic scenario ₹43.83. The calculation is refreshed regularly with new filings.
What is the revenue of Arvee Laboratories (India) Limited (ARVEE)?
Arvee Laboratories (India) Limited reported trailing-twelve-month revenue of about ₹315M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Arvee Laboratories (India) Limited (ARVEE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Arvee Laboratories (India) Limited it is ₹33.72 per share (as of Sep 27, 2026), against a price of ₹213.19. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Arvee Laboratories (India) Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, ARVEE trades above its calculated fair value: price ₹213.19, fair value ₹33.72, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ARVEE?
No. The price is what the market pays today (₹213.19); the fair value is what the company's own numbers justify (₹33.72). For Arvee Laboratories (India) Limited the two are ₹179.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Arvee Laboratories (India) Limited worth?
The market values Arvee Laboratories (India) Limited at about ₹2.4B (market capitalisation, as of Sep 27, 2026). Per share that is ₹213.19; our models calculate a fair value of ₹33.72 per share.
What do the bullish and bearish scenarios say about ARVEE?
Our models span a range for Arvee Laboratories (India) Limited: cautious scenario ₹23.60, base ₹33.72, optimistic ₹43.83 per share (as of Sep 27, 2026, price ₹213.19). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ARVEE?
Arvee Laboratories (India) Limited trades at a price-to-earnings ratio of 113.4 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹33.72 is built from several models across several years. Other multiples: P/B 7.0, P/S 7.5, EV/EBITDA 72.8.
How solid is the balance sheet of Arvee Laboratories (India) Limited (ARVEE)?
Balance-sheet figures for Arvee Laboratories (India) Limited (as of Sep 27, 2026): return on equity 7.8%, debt of 0.03 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is ARVEE from its 52-week high?
Arvee Laboratories (India) Limited trades at ₹213.19, about 27% below its 52-week high of ₹290.78 and 59% above the low of ₹133.86 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of ₹33.72 is for.
Which stocks are comparable to Arvee Laboratories (India) Limited?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Arvee Laboratories (India) Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹213.19, calculated fair value ₹33.72 (−84%), Quality Score 51/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ARVEE calculated?
We run Arvee Laboratories (India) Limited through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹33.72, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Arvee Laboratories (India) Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Arvee Laboratories (India) Limited (ARVEE)?
The closing price on Sep 25, 2026 was ₹213.19. Our model-based fair value is ₹33.72, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Arvee Laboratories (India) Limited right now?
The price sits above even our optimistic bull case (₹43.83). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹23.60 to ₹43.83) leaves room in how you read the outcome.
Key figures of Arvee Laboratories (India) Limited
How large is the market capitalisation of Arvee Laboratories (India) Limited (ARVEE)?
The market capitalisation of Arvee Laboratories (India) Limited is ₹2.4B (≈ $24.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Arvee Laboratories (India) Limited (ARVEE)?
The price-to-sales ratio of Arvee Laboratories (India) Limited is 9.09 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Arvee Laboratories (India) Limited (ARVEE)?
Earnings per share at Arvee Laboratories (India) Limited are ₹1.88 (price ÷ EPS = P/E 113.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Arvee Laboratories (India) Limited (ARVEE)?
The net margin of Arvee Laboratories (India) Limited is 8.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Arvee Laboratories (India) Limited (ARVEE)?
The return on equity (ROE) of Arvee Laboratories (India) Limited is 7.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Arvee Laboratories (India) Limited (ARVEE)?
On an EBIT basis the return on assets of Arvee Laboratories (India) Limited is 12.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Arvee Laboratories (India) Limited (ARVEE)?
The operating margin of Arvee Laboratories (India) Limited is 7.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Arvee Laboratories (India) Limited (ARVEE)?
Revenue at Arvee Laboratories (India) Limited is growing +67.5% versus a year earlier (3y avg −19.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Arvee Laboratories (India) Limited (ARVEE)?
Earnings per share at Arvee Laboratories (India) Limited are growing +684% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Arvee Laboratories (India) Limited (ARVEE) generate?
The free cash flow of Arvee Laboratories (India) Limited is −₹29.0M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Arvee Laboratories (India) Limited (ARVEE) hold?
Arvee Laboratories (India) Limited holds more cash than debt, ₹21.7M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Arvee Laboratories (India) Limited in the live analysis
One click puts Arvee Laboratories (India) Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
